Wednesday, February 8, 2012
Anacor Pharmaceuticals Inc., of Palo Alto, Calif., said it plans to focus on developing AN2728 for atopic dermatitis in 2012 and will defer the start of a planned Phase III trial in psoriasis, which was being designed under a special protocol assessment. The decision was based on the higher unmet need in atopic dermatitis and recent positive data from a Phase IIa atopic dermatitis trial. Anacor also released positive preliminary data from two safety studies of AN2728, showing it is well tolerated when applied to large body surface areas and sensitive skin.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.